News

Published on 27 May 2024 on Insider Monkey via Yahoo Finance

Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?


Article preview image

We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds.

Challenges in the Health Sector

The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World Health Organization report from December 2023, global health spending reached a new high in 2021 at $9.8 trillion or 10.3% of global gross domestic product (GDP). However, spending distribution remained highly unequal, with public health spending increasing worldwide, except in low-income countries where government health spending declined as it relied heavily on external health aid. In 2021, 11% of the global population lived in countries spending less than $50 per person annually on health, while high-income countries spent around $4,000 per capita. Additionally, low-income countries, despite having 8% of the global population, accounted for only 0.24% of global health expenditure. The report states that while there was a significant increase in public spending on health during the peak of the COVID-19 pandemic, this growth is unlikely to be sustained over the long term as countries now focus on economic challenges like slowing growth, high inflation, and increased debt servicing. Dr Bruce Aylward, WHO Assistant Director-General, Universal Health Coverage, Life Course said:

NASDAQ.CYTK price evolution
NASDAQ.AZN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
3 No-Brainer Stocks to Buy in June

You're probably familiar with the old adage, "April showers bring May flowers." And you probably ...

Motley Fool via Yahoo Finance 2 Jun 2024

AstraZeneca shares target raised by Argus on new drug approvals By Investing.com

On Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a mark...

Investing.com 30 May 2024

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by marke...

Motley Fool via Yahoo Finance 30 May 2024

Goldman Sachs Says Buy European Pharma Stocks Touting Innovation

(Bloomberg) -- European drugmakers that are focused on building portfolios of new medicines have ...

Bloomberg via Yahoo Finance 30 May 2024

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug Tuesday, ...

Benzinga via Yahoo Finance 29 May 2024

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca AZN reported overall survival (OS) data from a late-stage study, which evaluated its ...

Zacks via Yahoo Finance 29 May 2024

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significant...

Motley Fool via Yahoo Finance 29 May 2024

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (N...

Motley Fool via Yahoo Finance 29 May 2024

Why Is AstraZeneca Stock Trading Lower On Tuesday?

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical sign...

Benzinga via AOL 29 May 2024

Why Is AstraZeneca Stock Trading Lower On Tuesday?

Why Is AstraZeneca Stock Trading Lower On Tuesday? On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said ...

Benzinga via Yahoo Finance 28 May 2024